Epidemiology Data Slicer – Gastric Cancer
Epidemiology Data Slicer – Rheumatoid Arthritis
Epidemiology Data Slicer – Dermatitis
DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key bladder cancer patient populations covering 171 countries and more than 99%…
DRG Epidemiology’s coverage of actinic keratosis (AK) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany…
Since 2018, four novel calcitonin gene-related peptide (CGRP)-targeting monoclonal antibodies (MAbs)—Novartis / Amgen’s Aimovig, Eli Lilly’s Emgality, Teva’s Ajovy, and Lundbeck’s Vyepti…
Epidemiology Data Slicer – Multiple Sclerosis
Epidemiology Data Slicer – Chronic Heart Failure
DRG Epidemiology's coverage of atrial fibrillation comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of atrial fibrillation…
Clarivate Epidemiology’s coverage of acne comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of acne for each country, as well…
DRG Epidemiology’s coverage of fibromyalgia comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy,…
Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of hematological malignancies that can be broadly classified into indolent and aggressive subtypes. The treatment algorithm for B-cell…
Epidemiology Data Slicer – Psoriasis
The treatment of chronic pain continues to provide unique challenges to physicians owing to the heterogeneity of pain pathophysiology within and across different chronic pain subtypes and the…
A handful of newer disease-modifying therapies (DMTs) for multiple sclerosis (MS)—Novartis’s Mayzent, Bristol Myers Squibb’s Zeposia, Novartis’s Kesimpta, and Janssen’s Ponvory—have…